[VIRTUAL] A Multi-Center, Open-Label Study to Assess the Long-term Safety/Tolerability, and Pharmacokinetics, and Explore the Efficacy of Sofpironium Bromide Gel, 15% Applied Topically to Children and Adolescents, 9 to 16 Years of Age, with Primary Axillary Hyperhidrosis

Ecclock (sofpironium bromide) - Brickell, Kaken Pharma

Brandon Kirsch, MD1; Janet DuBois, MD2; Martin N. Zaiac, MD3; Deepak Chadha, MS, MBA, RAC1; Sanjeev Ahuja, MD, MBA, FACP1

May 29, 2021